Navigation Links
Study unveils SINE's potential of re-activating tumor fighting proteins within a cell

Arnhem, The Netherlands - New study suggests that selective blockade of CRM1-dependent nuclear export represents a completely novel, tumour metastasis-selective approach for the treatment of advanced metastatic prostate cancers.

According to the researchers, the human nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 (CRM1) is the sole exportin mediating transport of many multiple tumor suppressor proteins out of the nucleus. Their study aimed to verify the hypothesis that CRM1 inhibition could be beneficial for the treatment of prostate cancer metastases, which was achieved by testing the effects of the orally available, potent and selective, clinical stage SINE compound KPT 330.

"Although the class of compounds used in our studies SINEs or Selective Inhibitors of Nuclear Export have just recently entered early clinical testing, our results suggest that these agents could be active in patients with androgen-independent prostate cancer," commented study's lead author Dr. Claudio Festuccia, of the University of L'Aquila in Italy.

"Most of the current treatments for prostate cancer work by reducing the levels or blocking the receptors for a set of hormones called androgens. These SINE compounds act through an entirely new mechanism by re-activating a cells own tumor fighting proteins. These tumor fighting proteins, called tumor suppressor proteins, act as a guardian against the development of cancers by detecting damage to a cell's DNA and if DNA damage is found, activating the cell's own suicide program," he explained.

"Since all cancers have a great deal of DNA damage, re-activation of tumour suppressor proteins could cause the cancer to commit suicide. We observed just such an effect with these new SINE drug candidates."

According to the authors, the study also showed that these new SINE drug candidates prevented prostate cancer cells from causing damage to bones.

"The mechanisms of preventing the damage are now being worked out, but it appears that these new SINE drug candidates can suppress a type of bone cell called an osteoclast," said Festuccia.

Osteoclasts are activated by prostate cancer cells to destroy bone, and play an important role in prostate cancer-associated bone disease.


Contact: Evgenia Starkova
European Association of Urology

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
Breaking Medicine Technology: